Secretariat General DE LA Sante Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: Secretariat General DE LA Sante Pharmaceutical Import Records from India — 2 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Secretariat General DE LA Sante — Pharmaceutical Importer Profile (2026) | 2 Products, $1.8M Trade | TransData Nexus

Secretariat General DE LA Sante

Pharmaceutical Importer · Congo Dr · Antimalarial & Antiparasitic Focus · $1.8M Total Trade · DGFT Verified

Secretariat General DE LA Sante is a pharmaceutical importer based in Congo Dr with a total trade value of $1.8M across 2 products in 1 therapeutic categories. Based on 35 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Secretariat General DE LA Sante sources from 4 verified Indian suppliers, with Ipca Laboratories Limited accounting for 53.3% of imports.

Secretariat General DE LA Sante — Import Portfolio & Supplier Network

Secretariat General DE LA Sante import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Secretariat General DE LA Sante?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ipca Laboratories Limited	$879.5K	18	53.3%
Macleods Pharmaceuticals Limited	$441.6K	11	26.7%
Strides Pharma Science Limited

What Formulations Does Secretariat General DE LA Sante Import?

Formulation	Value	Ships
Drugs & pharma. harmless medicines- macsunate aq forte (artesunate 100MG and amodiaquine 270MG tablet)	$140.0K	3
Harmless medicines-artesunate 60MG powder for injection 1 vial	$100.0K	2
Harmless medicines-artesunate/amodiaquine 100MG/270MG tablets 6 x 25 tablet	$100.0K	2
Artecap artesunate rectal capsules [100MG][soft gelatin](138,299.00x 1x2's)	$78.8K	3
Harmless medicines artesunate 60MG	$50.0K	1
Artemether 20MG + lumefantrine 120MG TAB	$50.0K	1
Harmless medicines artesunate amodiaquine 50MG 135MG tablets 3 x 25 tablets	$50.0K	1
Artesunate 25MG + amodiaquine 67.50MG	$50.0K	1
Lumiter dt (artemether 20MG / lumefantrine 120MG dispersible tablets)ps: 30x12sbno:nad2345d md.02/23	$50.0K	1
Lumiter dt (artemether 20MG / lumefantrine 120MG dispersible tablets)bno:nad2345b md.02/23 ed.01/26 ps: 30x6s	$50.0K	1
Harmless medicines-artemether/lumefantrine 20/120MG tablets 30 x 18 tablet	$50.0K	1
Harmless medicines-artesunate/amodiaquine 100MG/270MG tablets 3 x 25 tablet	$50.0K	1
Harmless medicines-artesunate/amodiaquine 100MG+270MG tablets 3 x 25 tablet	$50.0K	1
Harmless medicines-artesunate/amodiaquine 50MG/135MG tablets 3 x 25 tablet	$50.0K	1
Artecap - artesunate rectal capsules [100MG][soft gelatin] (98,136.00 x 1 x 2's)	$50.0K	1

Secretariat General DE LA Sante imports 33 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Artesunate	Antimalarial & Antiparasitic	$1.4M	27	0.7%	2
2	Artemether	Antimalarial & Antiparasitic	$400.0K	8	0.0%	3

Secretariat General DE LA Sante imports 2 pharmaceutical products across 1 categories into Congo Dr totaling $1.8M.

Secretariat General DE LA Sante — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Secretariat General DE LA Sante is a governmental entity operating within the Ministry of Public Health, Hygiene, and Prevention of the Democratic Republic of Congo (DRC). It functions as the central procurement and distribution arm for pharmaceuticals, ensuring the availability of essential medicines across the country. Headquartered in Kinshasa, the capital city, the Secretariat General DE LA Sante plays a pivotal role in managing the national pharmaceutical supply chain, coordinating with various stakeholders to meet the healthcare needs of the Congolese population.

As a government procurement agency, its primary responsibility is to import, store, and distribute pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections. This centralized approach aims to streamline the supply chain, reduce costs, and maintain consistent quality standards for medicines distributed throughout the DRC. By overseeing the entire process—from importation to distribution—the Secretariat General DE LA Sante ensures equitable access to essential healthcare products nationwide.

2Distribution Network

The Secretariat General DE LA Sante operates a centralized distribution system from its main warehouse in Kinshasa, strategically located to serve as the primary hub for pharmaceutical imports and distribution. This centralization facilitates efficient management of inventory and ensures timely delivery of medicines to various regions within the DRC. While specific details about additional warehouse locations or logistics capabilities are not publicly disclosed, the centralized model suggests a focus on optimizing supply chain operations from the capital.

The distribution network is designed to cover the entire country, reaching both urban and rural areas. By maintaining a centralized warehouse, the Secretariat General DE LA Sante can effectively manage the flow of pharmaceutical products, ensuring that essential medicines are available where they are most needed. This approach aims to mitigate challenges related to infrastructure and transportation, striving to provide equitable access to healthcare resources across the DRC.

3Industry Role

In the DRC's pharmaceutical supply chain, the Secretariat General DE LA Sante serves as the primary wholesaler and distributor of pharmaceutical products. By centralizing procurement and distribution, it acts as the main conduit for importing and supplying finished pharmaceutical formulations to various healthcare facilities, including hospitals, clinics, and pharmacies. This centralized approach allows for standardized quality control, efficient inventory management, and equitable distribution of medicines throughout the country.

Additionally, the Secretariat General DE LA Sante collaborates with international suppliers to source a wide range of pharmaceutical products, ensuring that the DRC's healthcare system has access to essential medicines. Its role is crucial in maintaining the stability and reliability of the pharmaceutical supply chain, directly impacting the quality of healthcare services provided to the Congolese population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Secretariat General DE LA Sante

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The Secretariat General DE LA Sante's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.8 million USD from India across 35 shipments. This concentration is further emphasized by the top five imported products—Artesunate and Artemether—accounting for 100% of the portfolio. Such dependency on a limited number of suppliers and products can pose risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or logistical challenges.

However, this sourcing pattern may also reflect a strategic choice aimed at ensuring consistent quality and availability of critical antimalarial medications. The Secretariat General DE LA Sante's reliance on a select group of suppliers suggests established relationships and trust in the quality of products sourced from these manufacturers. Nonetheless, the lack of diversification in both suppliers and product categories indicates a potential vulnerability in the supply chain that could be addressed by exploring additional sourcing options and expanding the product portfolio.

2Supply Chain Resilience

The resilience of the Secretariat General DE LA Sante's supply chain is closely tied to its sourcing strategy. With a concentrated focus on two primary products—Artesunate and Artemether—sourced from four Indian suppliers, the supply chain's robustness is contingent upon the stability and reliability of these suppliers. The limited number of suppliers increases the risk of supply disruptions due to factors such as production issues, regulatory changes, or geopolitical tensions affecting trade routes.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is the primary body responsible for regulating pharmaceutical activities in the DRC. ACOREP oversees the authorization and control of drug imports and exports, ensuring that all pharmaceutical products meet the country's safety, efficacy, and quality standards. This includes the registration of pharmaceutical products, inspection of manufacturing facilities, and monitoring of market activities to prevent the circulation of counterfeit or substandard medicines.

The regulatory framework governing pharmaceutical imports in the DRC is designed to protect public health by enforcing stringent standards for drug quality and safety. Importers must comply with ACOREP's requirements, which include obtaining necessary licenses, ensuring Good Manufacturing Practice (GMP) certification, and adhering to labeling and documentation standards. This regulatory oversight is crucial for maintaining the integrity of the pharmaceutical supply chain and safeguarding the health of the Congolese population.

2Import Licensing & GMP

Import licensing in the DRC requires importers to obtain authorization from ACOREP, which involves submitting detailed documentation about the pharmaceutical products, including certificates of analysis, GMP certificates, and proof of registration in the country of origin. While GMP certification is officially required, enforcement can be inconsistent; a Certificate of Pharmaceutical Product (CPP) is a critical document. Additionally, importers must undergo a pre-shipment inspection by authorized bodies, such as Bureau Veritas, for shipments valued over a certain threshold. These procedures are designed to ensure that imported pharmaceuticals meet the DRC's quality and safety standards.

Secretariat General DE LA Sante — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

The Secretariat General DE LA Sante's focus on importing antimalarial and antiparasitic medications, specifically Artesunate and Artemether, aligns with the DRC's pressing healthcare needs. Malaria remains a significant public health challenge in the country, necessitating a reliable supply of effective treatments. By concentrating on these therapeutic areas, the Secretariat General DE LA Sante aims to address the high demand for antimalarial drugs, ensuring that patients have access to essential treatments.

This strategic focus also allows for streamlined procurement processes and potentially better pricing agreements with suppliers. However, the limited product range may restrict the agency's ability to respond to other emerging health concerns. Expanding the product portfolio to include a broader spectrum of

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Secretariat General DE LA Sante

What products does Secretariat General DE LA Sante import from India?

Secretariat General DE LA Sante imports 2 pharmaceutical products across 1 categories. Top imports: Artesunate ($1.4M), Artemether ($400.0K).

Who supplies pharmaceuticals to Secretariat General DE LA Sante from India?

Secretariat General DE LA Sante sources from 4 verified Indian suppliers. The primary supplier is Ipca Laboratories Limited (53.3% of imports, $879.5K).

What is Secretariat General DE LA Sante's total pharmaceutical import value?

Secretariat General DE LA Sante's total pharmaceutical import value from India is $1.8M, based on 35 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Secretariat General DE LA Sante focus on?

Secretariat General DE LA Sante imports across 1 categories. The largest: Antimalarial & Antiparasitic (100.0%).

Get Full Secretariat General DE LA Sante Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.